In study C2305, conducted in patients with active acromegaly who had not received medical therapy at study entry, biochemical control (defined as GH <2.5 μg/L and normal IGF-I) was achieved by a significantly greater proportion of patients receiving long-acting pasireotide than long-acting octreotide (31.3 vs 19.2%; P = 0.007) at month 12 (9). This evidence concerns the gene GH1 and acromegaly.